Hollings C. Renton, CEO of Onyx Pharmaceuticals, announced plans to retire next year. He will remain chairman of the board of directors. The company has initiated a search for his successor. Onyx has promoted Laura A. Brege to the newly-created position of executive vice president and CEO and Randy A. Kelley to senior vice president of sales and marketing. Onyx, together with Bayer, developed Nexavar, an approved live cancer therapy that made waves [1]Â at this year's ASCO conference.
- see this release [2] from Onyx
Related Articles:
Bayer, Onyx seek new Nexavar approval. Report [3]
Bayer, Onyx tout Nexavar data. Report [4]
Bayer, Onyx announce disappointing Nexavar results. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/cancer-stocks-gyrating-as-asco-abstracts-circulate/2007-05-18
[2] http://www.fiercebiotech.com/press-releases/press-release-onyx-pharma-ceo-hollings-renton-retire-promotes-laura-brege-coo
[3] http://www.fiercebiotech.com/story/spotlight-bayer-onyx-seek-new-nexavar-approval/2007-06-27
[4] http://www.fiercebiotech.com/story/bayer-onyx-tout-nexavar-data/2007-02-12
[5] http://www.fiercebiotech.com/story/bayer-onyx-announce-disappointing-nexavar-results/2006-12-04